Nivolumab/Ipilimumab vs Nivolumab Alone in Advanced Cancers

1. Pooled overall survival and progression-free survival HR were found to be 0.95 and 0.88 for nivolumab/ipilimumab vs. nivolumab. 2. Pooled OR for grade 3-4 adverse events was found to be 1.84 for the combination compared to monotherapy Evidence Rating Level: 1 (Excellent) Study Rundown: Nivolumab/ipilimumab combination therapy has demonstrated improved progression-free survival (PFS) and

Related Keywords

, Information Services , Cochrane Library , Rating Level , Five Year Survival , Combined Nivolumab , Combination Imunotherapy , Ctla4 , Pd 1 Inhibitors , Chronic Disease , Oncology ,